Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

heart failure - BNP guided management - all type of patients  


Related trials

TIME CHF, 2009 - BNP-guided management vs control

PROTECT, 2009 - BNP-guided management vs control

BATTLESCARRED, 2009 - BNP-guided management vs control

STARS-BNP, 2007 - BNP-guided management vs control

STARBRITE, 2007 - BNP-guided management vs control

Troughton, 2000 - BNP-guided management vs control

PRIMA, 0 - BNP-guided management vs control



See also:

  • All heart failure clinical trials
  • All clinical trials of BNP guided management
  • All clinical trials of BNP-guided management
    		•  

    PROTECT study, 2009

    [NCT00351390]

    Treatments

    Studied treatment natriuretic-peptide-guided therapy
    drug therapy titrated to achieve NT-proBNP <1000 pg/mL
    Control treatment standard management
    state-of-the art medical therapy, with device therapy at the physician's discretion, with adjustments to treatment based as usual on clinical judgment

    Patients

    Patients patients with NYHA class 2-4 heart failure, LVEF <40%, and history of at least one admission or outpatient diuretic dose increase for heart-failure destabilization in the previous six months
    Inclusion criteria Age > 21 years of age Left ventricular ejection fraction ˇÜ 40% NYHA class II-IV heart failure Hospital admission, Emergency Department visit, or outpatient diuretic escalation of therapy for destabilized HF at least once in the 6 months prior to enrollment
    Exclusion criteria Severe renal insufficiency defined as serum creatinine > 2.5 mg/dl Inoperable aortic valvular heart disease Life expectancy <1 year due to causes other than HF such as advanced cancer Cardiac transplantation or revascularization indicated or expected within 6 months Severe obstructive or restrictive pulmonary disease, defined as a forced expiratory volume in 1S <1 L when diagnosed as standard of care. Subject unable or unwilling to provide written informed consent Coronary revascularization (PCI or CABG) within the previous 3 months

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Number of centre single center
    Primary endpoint worsening HF, HF hospitalization, CV death


    Results

    No results available for this trial - no clinical endpoint reported



    Reference(s)

    Trials register # NCT00351390

    External links about this trial

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend